ID   TU-KATO-III
AC   CVCL_VL11
SY   TU-kato-III; TU-KatoIII; Tumorigenic-KATO-III
DR   BTO; BTO_0006122
DR   JCRB; JCRB1941
DR   Wikidata; Q98133684
RX   PubMed=17505008;
CC   Population: Japanese.
CC   Characteristics: Has a high tumorigenic potential. Established after seven tumor passages of KATO-III in nude mice.
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): JCRB=JCRB1941
ST   Amelogenin: X
ST   CSF1PO: 7,11
ST   D13S317: 8,12
ST   D16S539: 12
ST   D5S818: 10,11
ST   D7S820: 8,12
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C2993; Down syndrome
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
DI   ORDO; Orphanet_870; Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0371 ! KATO III
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 12
//
RX   PubMed=17505008; DOI=10.1158/1078-0432.CCR-06-2743;
RA   Takeda, Masayuki
RA   Arao, Tokuzo
RA   Yokote, Hideyuki
RA   Komatsu, Teruo
RA   Yanagihara, Kazuyoshi
RA   Sasaki, Hiroki
RA   Yamada, Yasuhide
RA   Tamura, Tomohide
RA   Fukuoka, Kazuya
RA   Kimura, Hiroshi
RA   Saijo, Nagahiro
RA   Nishio, Kazuto
RT   "AZD2171 shows potent antitumor activity against gastric cancer
RT   over-expressing fibroblast growth factor receptor 2/keratinocyte
RT   growth factor receptor.";
RL   Clin. Cancer Res. 13:3051-3057(2007).
//